Sachiko Taniguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sachiko Taniguchi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Avery Van Duzer
Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97239, USA
3 shared publications - Naoki Oshimori
Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR 97239, USA; Department of Dermatology, Oregon Health and Science University, Portland, OR 97239, USA; Department of Otolaryngology, Head & Neck Surgery, Oregon Health and Science University, Portland, OR 97239, USA; Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
3 shared publications Ajit Elhance
Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications- Justin J. Leitenberger
Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications - Sushil Kumar
Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications - Ajit Elhance
Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, USA
1 shared publication
Latest Publications
- 9 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 372 (6538)
Response to Comment on “Tumor-initiating cells establish an IL-33–TGF-β niche signaling loop to promote cancer progression”
Kamphuis et al . argue that macrophages accumulated in the proximity of tumor-initiating cells do not express the high-affinity immunoglobulin E receptor FcεRIα. Although we cannot exclude the possibility of nonspecific binding of anti-FcεRIα antibody (clone MAR-1), we provide evidence that macrophages in squamous cell carcinomas express FcεRIα and that IL-33 induces FcεRIα expression in bone marrow cell–derived macrophages.
- 9 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 372 (6538)
Response to Comment on “Tumor-initiating cells establish an IL-33–TGF-β niche signaling loop to promote cancer progression”
Kamphuis et al . argue that macrophages accumulated in the proximity of tumor-initiating cells do not express the high-affinity immunoglobulin E receptor FcεRIα. Although we cannot exclude the possibility of nonspecific binding of anti-FcεRIα antibody (clone MAR-1), we provide evidence that macrophages in squamous cell carcinomas express FcεRIα and that IL-33 induces FcεRIα expression in bone marrow cell–derived macrophages.
- Top Cited Papers
- 17 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6501) , 269-+
Tumor-initiating cells establish an IL-33–TGF-β niche signaling loop to promote cancer progression
Deconstructing a perilous loop: Cancer cells that give rise to solid tumors reside in a specialized microenvironment containing growth factors that support tumor growth and progression. The mechanisms by which tumor cells within this so-called “niche” attract and sustain these growth factors are poorly understood. Studying a mouse model of squamous cell carcinoma, Taniguchi et al. identified a signaling loop initiated by certain tumor cells within the niche that become more invasive on exposure to transforming growth factor β (TGF-β). They show that the tumor cells release the cytokine interleukin-33, which induces the differentiation of nearby myeloid cells into macrophages. These macrophages in turn release TGF-β, which feeds back to the tumor cells, promoting their malignant progression. Science this issue p. eaay1813
- 17 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6501) , 269-+
Top Cited PapersTumor-initiating cells establish an IL-33–TGF-β niche signaling loop to promote cancer progression
Deconstructing a perilous loop: Cancer cells that give rise to solid tumors reside in a specialized microenvironment containing growth factors that support tumor growth and progression. The mechanisms by which tumor cells within this so-called “niche” attract and sustain these growth factors are poorly understood. Studying a mouse model of squamous cell carcinoma, Taniguchi et al. identified a signaling loop initiated by certain tumor cells within the niche that become more invasive on exposure to transforming growth factor β (TGF-β). They show that the tumor cells release the cytokine interleukin-33, which induces the differentiation of nearby myeloid cells into macrophages. These macrophages in turn release TGF-β, which feeds back to the tumor cells, promoting their malignant progression. Science this issue p. eaay1813
- Open Access
- 2 December 2019
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 2 (6) , e201900582
ADAP1 promotes invasive squamous cell carcinoma progression and predicts patient survival
Invasive squamous cell carcinoma (SCC) is aggressive cancer with a high risk of recurrence and metastasis, but the critical determinants of its progression remain elusive. Here, we identify ADAP1, a GTPase-activating protein (GAP) for ARF6 up-regulated in TGF-β-responding invasive tumor cells, as a strong predictor of poor survival in early-stage SCC patients. Using a mouse model of SCC, we show that ADAP1 overexpression promotes invasive tumor progression by facilitating cell migration and breakdown of the basement membrane. We found that ADAP1-rich, TGF-β-responding tumor cells exhibit cytoplasmic laminin localization, which correlated with the absence of laminin and type IV collagen from the pericellular basement membrane. Interestingly, although tumors overexpressing a GAP activity-deficient mutant of ADAP1 resulted in morphologically complex tumors, those tumor cells failed to breach the basement membrane. Moreover,Adap1deletion in tumor cells ameliorated the basement membrane breakdown and had less invading cells in the stroma. Our study demonstrates that ADAP1 is a critical mediator of TGF-β-induced cancer invasion and might be exploited for the treatment of high-risk SCC.
- 2 December 2019
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 2 (6) , e201900582
Open AccessADAP1 promotes invasive squamous cell carcinoma progression and predicts patient survival
Invasive squamous cell carcinoma (SCC) is aggressive cancer with a high risk of recurrence and metastasis, but the critical determinants of its progression remain elusive. Here, we identify ADAP1, a GTPase-activating protein (GAP) for ARF6 up-regulated in TGF-β-responding invasive tumor cells, as a strong predictor of poor survival in early-stage SCC patients. Using a mouse model of SCC, we show that ADAP1 overexpression promotes invasive tumor progression by facilitating cell migration and breakdown of the basement membrane. We found that ADAP1-rich, TGF-β-responding tumor cells exhibit cytoplasmic laminin localization, which correlated with the absence of laminin and type IV collagen from the pericellular basement membrane. Interestingly, although tumors overexpressing a GAP activity-deficient mutant of ADAP1 resulted in morphologically complex tumors, those tumor cells failed to breach the basement membrane. Moreover,Adap1deletion in tumor cells ameliorated the basement membrane breakdown and had less invading cells in the stroma. Our study demonstrates that ADAP1 is a critical mediator of TGF-β-induced cancer invasion and might be exploited for the treatment of high-risk SCC.